ustekinumab-hmny (Starjemza) vs ustekinumab-srlf (Imuldosa)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-12 p40 · full Psoriasis pipeline

ustekinumab-hmny (Starjemza)

Marketed by Bio-Thera Solutions and partners

Approved in Psoriasismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

ustekinumab-srlf (Imuldosa)

Marketed by Accord BioPharma Inc. and partners

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT04785326 · Phase 3 · completed

Randomized, double-blind and controlled against the reference product Stelara in 598 patients, with a sample size calculated for the primary measure and exceeded. The primary measure, percent improvement in psoriasis severity (PASI), showed equivalence at both prespecified time points: difference -0.35 points at week 8 and -0.30 at week 12, each confidence interval inside its margin.

Reported efficacy

• To Evaluate Efficacy of DMB-3115 in Comparison With Stelara (Week 8 (For EMA) and 12 (For FDA)): Percent change in PASI, DMB-3115 vs Stelara: week 8 (EMA) 77.50% vs 77.85%, LS mean difference -0.35 (95% CI -3.60 to 2.90, margin -15 to 15); week 12 (FDA) 87.59% vs 87.89%, difference -0.30 (90% CI -2.37 to 1.76, margin -10 to 10); equivalence shown at both (Tichy et al., JAAD Int 2025). (met)

Result source: NCT04785326

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointustekinumab-hmny (Starjemza)ustekinumab-srlf (Imuldosa)
PASI 75—Not posted · NCT04728360—Not reported
PASI 90—Not posted · NCT04728360—Not reported
PASI 100—Not posted · NCT04728360—Not reported
sPGA 0/1—Not posted · NCT04728360—Not reported
DLQI, change—Not posted · NCT04728360—Not reported

PASI 75

ustekinumab-hmny (Starjemza)
—Not posted · NCT04728360
ustekinumab-srlf (Imuldosa)
—Not reported

PASI 90

ustekinumab-hmny (Starjemza)
—Not posted · NCT04728360
ustekinumab-srlf (Imuldosa)
—Not reported

PASI 100

ustekinumab-hmny (Starjemza)
—Not posted · NCT04728360
ustekinumab-srlf (Imuldosa)
—Not reported

sPGA 0/1

ustekinumab-hmny (Starjemza)
—Not posted · NCT04728360
ustekinumab-srlf (Imuldosa)
—Not reported

DLQI, change

ustekinumab-hmny (Starjemza)
—Not posted · NCT04728360
ustekinumab-srlf (Imuldosa)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ustekinumab-hmny (Starjemza): no structured comparison results are available for Psoriasis.

ustekinumab-srlf (Imuldosa): registry results are on file for Psoriasis, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ustekinumab-hmny (Starjemza)'s landscape · ustekinumab-srlf (Imuldosa)'s landscape